中文名稱:醋酸奧曲肽 | 英文名稱:Octreotide Acetate |
CAS:79517-01-4 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.87% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T4119 |
名稱 | Octreotide Acetate |
描述 | Octreotide Acetate (Sandostatin) is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone. |
動(dòng)物實(shí)驗(yàn) | Octreotide (acetate) is formulated in saline.MiceThirty mice with HCC xenografts are randomLy divided into three groups: (A) Octreotide-soln group, (B) Octreotide-PPSG group, and (C) control group. Octreotide-soln group receives i.p. injection of 100 μg/kg octreotide-soln once a day and totally for consecutive 14 days. Octreotide-PPSG group receives a single subcutaneous injection of 1.4 mg/kg Octreotide-PPSG, and the injection volume is about 0.2 mL. Control group receives i.p. injection of saline once a day for consecutive 14 days. Treatment starts on the next day after injection of H22 hepatoma cell suspension and maintains for 14 days. Tumor growth is monitored by periodic caliper measurements on day 7 and day 14 post seeding. Tumor volumes (V) are calculated based on the length and width of tumor by Eq. RatTwelve male SD rats are divided into two groups, and housed in standard cages at 25°C, with free access to food and water for a week prior to the experiment. Rats are subcutaneously injected with Octreotidereotide solution (Octreotide-soln) or Octreotide-PPSG at an equivalent single dose of 20 mg/kg. The dose is determined based on the clinical dose of Octreotide-soln in human. Rats are fasted for 12 h before dosing and food is returned approximately 2 h post dosing. Blood samples are collected at predetermined time points using heparinized Eppendorf tubes. Immediately after collection, the blood samples are placed on ice until centrifuged at 3000 g for 10 min within 1 h. The plasma is collected and stored at ?20°C until analysis. |
體內(nèi)活性 | Octreotide處理組與鹽水組相比,腫瘤體積顯著減少。Octreotide-PPSG(1.4 mg/kg,i.p.)的抗腫瘤效果超過(guò)Octreotide-soln(100 μg/kg,i.p.)。Octreotide處理在原發(fā)性HCC攜帶大鼠中顯著抑制SSTR2和SSTR5的表達(dá)水平,與鹽水組相比。Octreotide-PPSG對(duì)SSTR2和SSTR5的表達(dá)抑制作用大于Octreotide-soln處理組。 Octreotide Acetate 鹽試驗(yàn)劑量在2小時(shí)內(nèi)將血清胃泌素水平顯著降低至基線的約三分之一,效果持續(xù)約6小時(shí)。第21天,開(kāi)始使用持續(xù)釋放配方的 Octreotide Acetate 鹽(5 mg肌內(nèi)注射,每4周一次)。 |
存儲(chǔ)條件 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 29 mg/mL |
關(guān)鍵字 | inhibit | Octreotide | SMS-201995 | SMS201995 | Inhibitor | SSTR | Somatostatin Receptor | SSTRs | Octreotide Acetate | SMS 201-995 |
相關(guān)產(chǎn)品 | Cyclosomatostatin Acetate | BIM-23190 aceate | CYN 154806 TFA | FK962 | 2-Aminoethanethiol | Somatostatin acetate | (1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid | Cortistatin 14, human, rat acetate | L-796,778 | L-803087 |
相關(guān)庫(kù) | 環(huán)肽庫(kù) | JAK-STAT 化合物庫(kù) | 多肽分子庫(kù) | 臨床前化合物庫(kù) | NO PAINS 化合物庫(kù) | 大環(huán)化合物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.2651萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營(yíng)模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥800 |
VIP6年
|
杭州信海醫(yī)藥科技有限公司
|
2024-11-17 | |
詢價(jià) |
VIP2年
|
上海鴻肽生物科技有限公司
|
2024-11-16 | |
詢價(jià) |
VIP4年
|
武漢裕清嘉衡藥業(yè)有限公司
|
2024-11-16 | |
詢價(jià) |
VIP4年
|
武漢東康源科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP2年
|
浙江杰坤生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP3年
|
紹興市均宇生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP3年
|
南京源肽生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP2年
|
中科華藥(江蘇)生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP1年
|
深圳市恒豐萬(wàn)達(dá)醫(yī)藥科技有限公司
|
2024-11-14 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2024-11-13 |